Innospec Inc.

18 days ago · zacks.com

Innospec (IOSP) reported earnings 30 days ago. What's next for the stock?

1 month ago · seekingalpha.com

With the oilfield segment leading topline growth, even more growth should be expected as the adoption of DRA expands and the firm re-enters the Mexico market. In Q2 of 2026, revenue grew 12%, beating estimates by $34.17 million. The firm is now in a better financial position to command a higher sales multiple. The Performance chemical segment still experiences volume declines, raising concerns about the firm over investing by adding 10% capacity in a weak market.

2 months ago · zacks.com

Innospec's Q2 earnings beat estimates as all three businesses delivered revenue growth, while a debt-free balance sheet supports further investment.

2 months ago · zacks.com

Here is how Innospec (IOSP) and Ingevity (NGVT) have performed compared to their sector so far this year.

2 months ago · defenseworld.net

Arrowstreet Capital Limited Partnership lifted its holdings in Innospec Inc. (NASDAQ: IOSP) by 196.5% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,497 shares of the specialty chemicals company's stock after purchasing an additional 12,259 shares during the period. Arrowstreet Capital Limited Partnership owned

2 months ago · seekingalpha.com

Innospec Inc. (IOSP) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Innospec NASDAQ: IOSP reported higher second-quarter revenue and net income as all three operating segments posted double-digit sales growth and operating-income gains, while the company continued repair and optimization work at its North Carolina Performance Chemicals facilities.

2 months ago · zacks.com

Innospec (IOSP) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.26 per share a year ago.

2 months ago · globenewswire.com

Strong contributions from all businesses with revenues up 12 percent and operating income up 16 percent

2 months ago · zacks.com

Innospec (IOSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.